{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T17:46:52Z","timestamp":1792259212246,"version":"4.4.0"},"reference-count":99,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:00:00Z","timestamp":1779062400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:00:00Z","timestamp":1779062400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Ther"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s40744-026-00860-3","type":"journal-article","created":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T17:25:45Z","timestamp":1779125145000},"page":"931-949","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cutaneous Manifestations in Psoriatic Arthritis: Phenotypes, Clinical Burden, and Therapeutic Implications"],"prefix":"10.1007","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-3386-597X","authenticated-orcid":false,"given":"Konstantinos","family":"Tsafis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-2368-7064","authenticated-orcid":false,"given":"Vasileios","family":"Skepastianos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0476-154X","authenticated-orcid":false,"given":"Elpida","family":"Skouvaklidou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1379-4888","authenticated-orcid":false,"given":"Dimitrios","family":"Deligeorgakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4577-2324","authenticated-orcid":false,"given":"Maria","family":"Boutel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-5312-1236","authenticated-orcid":false,"given":"Aikaterini","family":"Kontonikola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-1175-2285","authenticated-orcid":false,"given":"Nikolaos","family":"Papazoglou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4932-7023","authenticated-orcid":false,"given":"George E.","family":"Fragoulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5275-8639","authenticated-orcid":false,"given":"Nikolaos","family":"Kougkas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,18]]},"reference":[{"issue":"1","key":"860_CR1","doi-asserted-by":"publisher","first-page":"65","DOI":"10.7861\/clinmedicine.17-1-65","volume":"17","author":"LC Coates","year":"2017","unstructured":"Coates LC, Helliwell PS. Psoriatic arthritis: state of the art review. Clin Med (Lond). 2017;17(1):65\u201370.","journal-title":"Clin Med (Lond)."},{"issue":"2","key":"860_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2021.101670","volume":"35","author":"M Kishimoto","year":"2021","unstructured":"Kishimoto M, Deshpande GA, Fukuoka K, et al. Clinical features of psoriatic arthritis. Best Pract Res Clin Rheumatol. 2021;35(2):101670.","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"860_CR3","first-page":"keae198","volume":"26","author":"S Lembke","year":"2024","unstructured":"Lembke S, Macfarlane GJ, Jones GT. The worldwide prevalence of psoriatic arthritis\u2014a systematic review and meta-analysis. Rheumatology (Oxford). 2024;26:keae198.","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"860_CR4","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/j.jaad.2013.07.023","volume":"69","author":"PJ Mease","year":"2013","unstructured":"Mease PJ, Gladman DD, Papp KA, et al. Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European\/North American dermatology clinics. J Am Acad Dermatol. 2013;69(5):729\u201335.","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"860_CR5","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1002\/art.24608","volume":"61","author":"G Ibrahim","year":"2009","unstructured":"Ibrahim G, Waxman R, Helliwell PS. The prevalence of psoriatic arthritis in people with psoriasis. Arthritis Rheumatol. 2009;61(10):1373\u20138.","journal-title":"Arthritis Rheumatol"},{"issue":"21\u201322","key":"860_CR6","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1007\/s00508-016-1111-9","volume":"128","author":"A Kerschbaumer","year":"2016","unstructured":"Kerschbaumer A, Fenzl KH, Erlacher L, Aletaha D. An overview of psoriatic arthritis\u2014epidemiology, clinical features, pathophysiology and novel treatment targets. Wien Klin Wochenschr. 2016;128(21\u201322):791\u20135.","journal-title":"Wien Klin Wochenschr"},{"issue":"2","key":"860_CR7","doi-asserted-by":"publisher","first-page":"101692","DOI":"10.1016\/j.berh.2021.101692","volume":"35","author":"P Karmacharya","year":"2021","unstructured":"Karmacharya P, Chakradhar R, Ogdie A. The epidemiology of psoriatic arthritis: a literature review. Best Pract Res Clin Rheumatol. 2021;35(2):101692.","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"3","key":"860_CR8","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1111\/j.1346-8138.2011.01483.x","volume":"39","author":"S Morizane","year":"2012","unstructured":"Morizane S, Gallo RL. Antimicrobial peptides in the pathogenesis of psoriasis. J Dermatol. 2012;39(3):225\u201330.","journal-title":"J Dermatol"},{"issue":"9","key":"860_CR9","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1038\/ni1488","volume":"8","author":"L Zhou","year":"2007","unstructured":"Zhou L, Ivanov II, Spolski R, et al. IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat Immunol. 2007;8(9):967\u201374.","journal-title":"Nat Immunol"},{"issue":"6","key":"860_CR10","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1111\/1346-8138.15913","volume":"48","author":"K Yamanaka","year":"2021","unstructured":"Yamanaka K, Yamamoto O, Honda T. Pathophysiology of psoriasis: a review. J Dermatol. 2021;48(6):722\u201331.","journal-title":"J Dermatol"},{"issue":"12","key":"860_CR11","doi-asserted-by":"publisher","first-page":"2741","DOI":"10.1038\/jid.2013.237","volume":"133","author":"CQF Wang","year":"2013","unstructured":"Wang CQF, Akalu YT, Suarez-Farinas M, et al. IL-17 and TNF synergistically modulate cytokine expression while suppressing melanogenesis: potential relevance to psoriasis. J Investig Dermatol. 2013;133(12):2741\u201352.","journal-title":"J Investig Dermatol"},{"issue":"3","key":"860_CR12","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/jid.2010.340","volume":"131","author":"A Chiricozzi","year":"2011","unstructured":"Chiricozzi A, Guttman-Yassky E, Su\u00e1rez-Fari\u00f1as M, et al. Integrative responses to IL-17 and TNF-\u03b1 in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis. J Investig Dermatol. 2011;131(3):67.","journal-title":"J Investig Dermatol"},{"issue":"11","key":"860_CR13","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.3390\/biomedicines9111511","volume":"9","author":"A Campanati","year":"2021","unstructured":"Campanati A, Marani A, Martina E, Diotallevi F, Radi G, Offidani A. Psoriasis as an immune-mediated and inflammatory systemic disease: from pathophysiology to novel therapeutic approaches. Biomedicines. 2021;9(11):1511.","journal-title":"Biomedicines"},{"issue":"Suppl 5","key":"860_CR14","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/jdv.12562","volume":"28","author":"M Rouzaud","year":"2014","unstructured":"Rouzaud M, Sevrain M, Villani AP, et al. Is there a psoriasis skin phenotype associated with psoriatic arthritis? Systematic literature review. J Eur Acad Dermatol Venereol. 2014;28(Suppl 5):17\u201326.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"860_CR15","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/j.jaad.2013.07.023","volume":"69","author":"PJ Mease","year":"2013","unstructured":"Mease PJ, Gladman DD, Papp KA, et al. Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European\/North American dermatology clinics. J Am Acad Dermatol. 2013;69(5):729\u201335.","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"860_CR16","first-page":"1752","volume":"26","author":"MR Cohen","year":"1999","unstructured":"Cohen MR, Reda DJ, Clegg DO. Baseline relationships between psoriasis and psoriatic arthritis: analysis of 221 patients with active psoriatic arthritis. Department of Veterans Affairs Cooperative Study Group on Seronegative Spondyloarthropathies. J Rheumatol. 1999;26(8):1752\u20136.","journal-title":"J Rheumatol"},{"issue":"3","key":"860_CR17","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/s41584-019-0175-0","volume":"15","author":"JU Scher","year":"2019","unstructured":"Scher JU, Ogdie A, Merola JF, Ritchlin C. Preventing psoriatic arthritis: focusing on patients with psoriasis at increased risk of transition. Nat Rev Rheumatol. 2019;15(3):153\u201366.","journal-title":"Nat Rev Rheumatol"},{"issue":"4","key":"860_CR18","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1002\/acr.20401","volume":"63","author":"L Eder","year":"2011","unstructured":"Eder L, Chandran V, Shen H, et al. Incidence of arthritis in a prospective cohort of psoriasis patients. Arthritis Care Res (Hoboken). 2011;63(4):619\u201322.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"3","key":"860_CR19","doi-asserted-by":"publisher","first-page":"159","DOI":"10.2165\/00128071-200102030-00005","volume":"2","author":"PC van de Kerkhof","year":"2001","unstructured":"van de Kerkhof PC, Franssen ME. Psoriasis of the scalp. Am J Clin Dermatol. 2001;2(3):159\u201365.","journal-title":"Am J Clin Dermatol"},{"issue":"Suppl 2","key":"860_CR20","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1111\/j.1468-3083.2009.03565.x","volume":"24","author":"S Prey","year":"2010","unstructured":"Prey S, Paul C, Bronsard V, et al. Assessment of risk of psoriatic arthritis in patients with plaque psoriasis: a systematic review. J Eur Acad Dermatol Venereol. 2010;24(Suppl 2):31\u20135.","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"860_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.649408","volume":"8","author":"BX Yan","year":"2021","unstructured":"Yan BX, Chen XY, Ye LR, Chen JQ, Zheng M, Man XY. Cutaneous and systemic psoriasis: classifications and classification for the distinction. Front Med. 2021;8:649408.","journal-title":"Front Med"},{"issue":"19","key":"860_CR22","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1001\/jama.2020.4006","volume":"323","author":"AW Armstrong","year":"2020","unstructured":"Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA. 2020;323(19):1945\u201360.","journal-title":"JAMA"},{"key":"860_CR23","first-page":"131","volume":"6","author":"KE Benjegerdes","year":"2016","unstructured":"Benjegerdes KE, Hyde K, Kivelevitch D, Mansouri B. Pustular psoriasis: pathophysiology and current treatment perspectives. Psoriasis (Auckland). 2016;6:131\u201344.","journal-title":"Psoriasis (Auckland)"},{"issue":"8","key":"860_CR24","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.3390\/vaccines10081171","volume":"0","author":"P Gisondi","year":"2022","unstructured":"Gisondi P, Bellinato F, Girolomoni G. Clinical characteristics of patients with pustular psoriasis: a single-center retrospective observational study. Vaccines (Basel). 2022;0(8):1171.","journal-title":"Vaccines (Basel)"},{"key":"860_CR25","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.clindermatol.2016.09.004","volume":"1","author":"B Engin","year":"2017","unstructured":"Engin B, A\u015fk\u0131n \u00d6, T\u00fcz\u00fcn Y. Palmoplantar psoriasis. Clin Dermatol. 2017;1:19\u201327.","journal-title":"Clin Dermatol"},{"issue":"3","key":"860_CR26","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1684\/ejd.2021.4056","volume":"31","author":"A Karamanakos","year":"2021","unstructured":"Karamanakos A, Vergou T, Panopoulos S, Tektonidou MG, Stratigos AJ, Sfikakis PP. Psoriasis as an adverse reaction to biologic agents beyond anti-TNF-\u03b1 therapy. Eur J Dermatol. 2021;31(3):307\u201317.","journal-title":"Eur J Dermatol"},{"issue":"5","key":"860_CR27","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/j.jaad.2020.12.010","volume":"86","author":"MJ Murphy","year":"2022","unstructured":"Murphy MJ, Cohen JM, Vesely MD, Damsky W. Paradoxical eruptions to targeted therapies in dermatology: a systematic review and analysis. J Am Acad Dermatol. 2022;86(5):1080\u201391.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"860_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-02466-4","volume":"9","author":"C Conrad","year":"2018","unstructured":"Conrad C, Di Domizio J, Mylonas A, et al. TNF blockade induces a dysregulated type\u00a0I interferon response without autoimmunity in paradoxical psoriasis. Nat Commun. 2018;9(1):25.","journal-title":"Nat Commun"},{"issue":"6","key":"860_CR29","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.3390\/ijms20061475","volume":"20","author":"A Rendon","year":"2019","unstructured":"Rendon A, Sch\u00e4kel K. Psoriasis pathogenesis and treatment. Int J Mol Sci. 2019;20(6):1475.","journal-title":"Int J Mol Sci"},{"key":"860_CR30","doi-asserted-by":"publisher","first-page":"953","DOI":"10.2147\/CCID.S189000","volume":"12","author":"G Micali","year":"2019","unstructured":"Micali G, Verz\u00ec AE, Giuffrida G, Panebianco E, Musumeci ML, Lacarrubba F. Inverse psoriasis: from diagnosis to current treatment options. Clin Cosmet Investig Dermatol. 2019;12:953\u20139.","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"2","key":"860_CR31","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1002\/art.24172","volume":"61","author":"FC Wilson","year":"2009","unstructured":"Wilson FC, Icen M, Crowson CS, McEvoy MT, Gabriel SE, Kremers HM. Incidence and clinical predictors of psoriatic arthritis in patients with psoriasis: a population-based study. Arthritis Rheum. 2009;61(2):233\u20139.","journal-title":"Arthritis Rheum"},{"issue":"7","key":"860_CR32","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/S1473-3099(10)70101-8","volume":"10","author":"N Morar","year":"2010","unstructured":"Morar N, Willis-Owen SA, Maurer T, Bunker CB. HIV-associated psoriasis: pathogenesis, clinical features, and management. Lancet Infect Dis. 2010;10(7):470\u20138.","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"860_CR33","doi-asserted-by":"publisher","first-page":"311","DOI":"10.7861\/clinmedicine.15-3-311","volume":"15","author":"A Zampetti","year":"2015","unstructured":"Zampetti A, Tiberi S. Inverse psoriasis. Clin Med. 2015;15(3):311.","journal-title":"Clin Med"},{"key":"860_CR34","first-page":"93","volume":"6","author":"RK Singh","year":"2016","unstructured":"Singh RK, Lee KM, Ucmak D, et al.\u00a0Erythrodermic psoriasis: pathophysiology and current treatment perspectives. Psoriasis (Auckland). 2016;6:93\u2013104.","journal-title":"Psoriasis (Auckland)"},{"issue":"6","key":"860_CR35","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/j.clindermatol.2007.08.003","volume":"25","author":"L Naldi","year":"2007","unstructured":"Naldi L, Gambini D. The clinical spectrum of psoriasis. Clin Dermatol. 2007;25(6):510\u20138.","journal-title":"Clin Dermatol"},{"issue":"6","key":"860_CR36","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/s40265-020-01283-2","volume":"80","author":"S Shao","year":"2020","unstructured":"Shao S, Wang G, Maverakis E, Gudjonsson JE. Targeted treatment for erythrodermic psoriasis: rationale and recent advances. Drugs. 2020;80(6):525\u201334.","journal-title":"Drugs"},{"key":"860_CR37","first-page":"120347542412661","volume":"30","author":"T Zhou","year":"2024","unstructured":"Zhou T, Koussiouris J, Kim L, Vender R. Management of guttate psoriasis: a systematic review. Cutan Med Surg. 2024;30:12034754241266188.","journal-title":"Cutan Med Surg"},{"issue":"10","key":"860_CR38","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1111\/j.1346-8138.2010.00871.x","volume":"37","author":"HC Ko","year":"2010","unstructured":"Ko HC, Jwa SW, Song M, Kim MB, Kwon KS. Clinical course of guttate psoriasis: long-term follow-up study. J Dermatol. 2010;37(10):894\u20139.","journal-title":"J Dermatol"},{"issue":"8 Suppl","key":"860_CR39","first-page":"s216","volume":"22","author":"A Menter","year":"2016","unstructured":"Menter A. Psoriasis and psoriatic arthritis overview. Am J Manag Care. 2016;22(8 Suppl):s216\u201324.","journal-title":"Am J Manag Care"},{"issue":"9","key":"860_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/ijd.15860","volume":"61","author":"N Hanna","year":"2022","unstructured":"Hanna N, Silverberg OM, Reaume M, et al. Incidence, prevalence, and predictors of inflammatory arthritis in patients with hidradenitis suppurativa: a systematic review and meta-analysis. Int J Dermatol. 2022;61(9):1.","journal-title":"Int J Dermatol"},{"issue":"2","key":"860_CR41","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1093\/bjd\/ljad345","volume":"190","author":"JG Krueger","year":"2024","unstructured":"Krueger JG, Frew J, Jemec GBE, et al. Hidradenitis suppurativa: new insights into disease mechanisms and an evolving treatment landscape. Br J Dermatol. 2024;190(2):149\u201362.","journal-title":"Br J Dermatol"},{"key":"860_CR42","doi-asserted-by":"publisher","unstructured":"Meier K, Schloegl A, Poddubnyy D, Ghoreschi K. Skin manifestations in spondyloarthritis. Ther Adv Musculoskelet Dis. 2020;12. https:\/\/doi.org\/10.1177\/1759720X209759.","DOI":"10.1177\/1759720X209759"},{"key":"860_CR43","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1097\/01.MIB.0000436959.62286.f9","volume":"20","author":"AV Marzano","year":"2014","unstructured":"Marzano AV, Borghi A, Stadnicki A, Crosti C, Cugno M. Cutaneous manifestations in patients with inflammatory bowel diseases: pathophysiology, clinical features, and therapy. Inflamm Bowel Dis. 2014;20:213\u201327.","journal-title":"Inflamm. Bowel Dis."},{"issue":"10","key":"860_CR44","doi-asserted-by":"publisher","first-page":"3963","DOI":"10.1007\/s10067-021-05768-7","volume":"40","author":"E Sawka","year":"2021","unstructured":"Sawka E, Zhou A, Latour E, Friedman M, Ortega-Loayza AG. Inflammatory arthritis-associated pyoderma gangrenosum: a systematic review. Clin Rheumatol. 2021;40(10):3963\u20139.","journal-title":"Clin Rheumatol"},{"key":"860_CR45","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01059","volume":"10","author":"AV Marzano","year":"2019","unstructured":"Marzano AV, Ortega-Loayza AG, Heath M, Morse D, Genovese G, Cugno M. Mechanisms of inflammation in neutrophil-mediated skin diseases. Front Immunol. 2019;10:1059.","journal-title":"Front Immunol"},{"issue":"10","key":"860_CR46","first-page":"1170","volume":"21","author":"M Augustin","year":"2023","unstructured":"Augustin M, Lindner L, K\u00fchl L, et al. Characterization of patients with psoriatic arthritis in dermatologic and rheumatologic care: analysis of two registries. J Dtsch Dermatol Ges. 2023;21(10):1170\u20136.","journal-title":"J Dtsch Dermatol Ges"},{"key":"860_CR47","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1159\/000512930","volume":"237","author":"JT Maul","year":"2021","unstructured":"Maul JT, Anzengruber F, Conrad C, et al.\u00a0Topical treatment of psoriasis vulgaris: The Swiss Treatment Pathway. Dermatology. 2021;237:166\u201378.","journal-title":"Dermatology"},{"key":"860_CR48","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1111\/ijd.12790","volume":"54","author":"T Soleymani","year":"2015","unstructured":"Soleymani T, Hung T, Soung J. The role of vitamin D in psoriasis: a review. Int J Dermatol. 2015;54:383\u201392.","journal-title":"Int J Dermatol."},{"key":"860_CR49","doi-asserted-by":"crossref","unstructured":"Amiri D, Schwarz CW, Gether L, Skov L. Safety and efficacy of topical calcineurin inhibitors in the treatment of facial and genital psoriasis: a systematic review. Acta Derm Venereol. 2003;103:adv00890.","DOI":"10.2340\/actadv.v103.6525"},{"issue":"2","key":"860_CR50","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.jaad.2018.03.040","volume":"79","author":"LS Gold","year":"2018","unstructured":"Gold LS, Lebwohl MG, Sugarman JL, et al. Safety and efficacy of a fixed combination of halobetasol and tazarotene in the treatment of moderate-to-severe plaque psoriasis: results of 2 phase\u00a03 randomized controlled trials. J Am Acad Dermatol. 2018;79(2):28.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"860_CR51","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.jaad.2019.11.024","volume":"82","author":"CA Elmets","year":"2020","unstructured":"Elmets CA, Lim HW, Stoff B, et al. Joint American Academy of Dermatology\u2013National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis with phototherapy. J Am Acad Dermatol. 2020;82(3):780.","journal-title":"J Am Acad Dermatol"},{"key":"860_CR52","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41584-022-00798-0","volume":"18","author":"LC Coates","year":"2022","unstructured":"Coates LC, Soriano ER, Corp N, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. Nat Rev Rheumatol. 2022;18:465\u201379.","journal-title":"Nat Rev Rheumatol"},{"key":"860_CR53","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/j.jaad.2018.11.057","volume":"80","author":"A Menter","year":"2019","unstructured":"Menter A, Strober BE, Kaplan DH, et al. Joint American Academy of Dermatology\u2013National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80:1029\u201372.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"860_CR54","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1016\/j.jaad.2020.02.044","volume":"82","author":"A Menter","year":"2020","unstructured":"Menter A, Gelfand JM, Connor C, et al. Joint American Academy of Dermatology\u2014National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies. J Am Acad Dermatol. 2020;82(6):1445\u201386.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"860_CR55","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.jaad.2011.04.004","volume":"66","author":"RS Stern","year":"2012","unstructured":"Stern RS. PUVA follow-up study. The risk of squamous cell and basal cell cancer associated with psoralen and ultraviolet A therapy: a 30-year prospective study. J Am Acad Dermatol. 2012;66(4):553\u201362.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"860_CR56","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1136\/ard-2024-225531","volume":"83","author":"L Gossec","year":"2024","unstructured":"Gossec L, Kerschbaumer A, Ferreira RJO, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update. Ann Rheum Dis. 2024;83(6):706\u201319.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"860_CR57","first-page":"CD012722","volume":"1","author":"TD Wilsdon","year":"2019","unstructured":"Wilsdon TD, Whittle SL, Thynne TR, Mangoni AA. Methotrexate for psoriatic arthritis. Cochrane Database Syst Rev. 2019;1(1):CD012722.","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"860_CR58","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1586\/1744666X.2016.1117941","volume":"12","author":"F Caso","year":"2016","unstructured":"Caso F, Lubrano E, Del Puente A, et al. Progress in understanding and utilizing TNF-\u03b1 inhibition for the treatment of psoriatic arthritis. Expert Rev Clin Immunol. 2016;12(3):315\u201331.","journal-title":"Expert Rev Clin Immunol"},{"issue":"3","key":"860_CR59","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s13555-017-0198-x","volume":"7","author":"A Menter","year":"2017","unstructured":"Menter A, Tha\u00e7i D, Wu JJ, et al. Long-term safety and effectiveness of adalimumab for moderate to severe psoriasis: results from 7-year interim analysis of the ESPRIT Registry. Dermatol Ther (Heidelb). 2017;7(3):365\u201381.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"1","key":"860_CR60","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.gendis.2020.02.004","volume":"8","author":"H Zhang","year":"2020","unstructured":"Zhang H, Shi N, Diao Z, Chen Y, Zhang Y. Therapeutic potential of TNF\u03b1 inhibitors in chronic inflammatory disorders: past and future. Genes Dis. 2020;8(1):38\u201347.","journal-title":"Genes Dis"},{"issue":"8","key":"860_CR61","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/s41577-024-01008-6","volume":"24","author":"MF Neurath","year":"2024","unstructured":"Neurath MF. Strategies for targeting cytokines in inflammatory bowel disease. Nat Rev Immunol. 2024;24(8):559\u201376.","journal-title":"Nat Rev Immunol"},{"issue":"8","key":"860_CR62","first-page":"e42791","volume":"15","author":"A Chokshi","year":"2023","unstructured":"Chokshi A, et al. Paradoxical tumor necrosis factor-alpha (TNF-\u03b1) inhibitor-induced psoriasis: a systematic review of pathogenesis, clinical presentation, and treatment. Cureus. 2023;15(8):e42791.","journal-title":"Cureus"},{"issue":"9","key":"860_CR63","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1001\/jamadermatol.2015.0718","volume":"151","author":"RE Kalb","year":"2015","unstructured":"Kalb RE, Fiorentino DF, Lebwohl MG, et al. Risk of serious infection with biologic and systemic treatment of psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR). JAMA Dermatol. 2015;151(9):961\u20139.","journal-title":"JAMA Dermatol"},{"issue":"9894","key":"860_CR64","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/S0140-6736(13)60594-2","volume":"382","author":"IB McInnes","year":"2013","unstructured":"McInnes IB, Kavanaugh A, Gottlieb AB, et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1\u00a0year results of the phase\u00a03, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet. 2013;382(9894):780\u20139.","journal-title":"Lancet"},{"issue":"1","key":"860_CR65","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1111\/jdv.16558","volume":"35","author":"J Bagel","year":"2021","unstructured":"Bagel J, Blauvelt A, Nia J, et al. Secukinumab maintains superiority over ustekinumab in clearing skin and improving quality of life in patients with moderate to severe plaque psoriasis: 52-week results from a double-blind phase\u00a03b trial (CLARITY). J Eur Acad Dermatol Venereol. 2021;35(1):135\u201342.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"860_CR66","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1111\/bjd.12214","volume":"168","author":"KA Papp","year":"2013","unstructured":"Papp KA, Griffiths CE, Gordon K, et al. Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5\u00a0years of follow-up. Br J Dermatol. 2013;168(4):844\u201354.","journal-title":"Br J Dermatol"},{"issue":"11","key":"860_CR67","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1111\/ijd.16849","volume":"62","author":"AG Vaiopoulos","year":"2023","unstructured":"Vaiopoulos AG, Dalamaga M, Katsimbri P, et al. Real-world data show high efficacy of IL23 inhibitors guselkumab and risankizumab in psoriatic arthritis and difficult-to-treat areas. Int J Dermatol. 2023;62(11):1404\u201313.","journal-title":"Int J Dermatol"},{"issue":"4","key":"860_CR68","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s12026-023-09366-4","volume":"71","author":"X Huang","year":"2023","unstructured":"Huang X, Shentu H, He Y, et al.\u00a0Efficacy and safety of IL-23 inhibitors in the treatment of psoriatic arthritis: a meta-analysis based on randomized controlled trials. Immunol Res. 2023;71(4):505\u201315.","journal-title":"Immunol Res"},{"issue":"10510","key":"860_CR69","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1016\/S0140-6736(25)01576-4","volume":"406","author":"LS Gold","year":"2025","unstructured":"Gold LS, Armstrong AW, Bissonnette R, et al. Once-daily oral icotrokinra versus placebo and once-daily oral deucravacitinib in participants with moderate-to-severe plaque psoriasis (ICONIC-ADVANCE 1 & 2): two phase\u00a03, randomised, placebo-controlled and active-comparator-controlled trials. Lancet. 2025;406(10510):1363\u201374.","journal-title":"Lancet"},{"key":"860_CR70","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-65269-6","volume":"10","author":"L Chen","year":"2020","unstructured":"Chen L, Deshpande M, Grisotto M, et al. Skin expression of IL-23 drives the development of psoriasis and psoriatic arthritis in mice. Sci Rep. 2020;10:8259.","journal-title":"Sci Rep"},{"issue":"3","key":"860_CR71","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1093\/rheumatology\/keae257","volume":"64","author":"A Floris","year":"2025","unstructured":"Floris A, Mugheddu C, Sichi L, et al. Treatment of psoriasis with different classes of biologics reduces the likelihood of peripheral and axial psoriatic arthritis development. Rheumatology (Oxford). 2025;64(3):1131\u20137.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"860_CR72","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s40744-016-0031-5","volume":"3","author":"P Mease","year":"2016","unstructured":"Mease P, McInnes IB. Secukinumab: a new treatment option for psoriatic arthritis. Rheumatol Ther. 2016;3(1):5\u201329.","journal-title":"Rheumatol Ther"},{"issue":"3","key":"860_CR73","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1111\/bjd.16050","volume":"178","author":"KA Papp","year":"2018","unstructured":"Papp KA, Leonardi CL, Blauvelt A, et al. Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double-blinded, controlled studies (UNCOVER-1, UNCOVER-2, UNCOVER-3). Br J Dermatol. 2018;178(3):674\u201381.","journal-title":"Br J Dermatol"},{"key":"860_CR74","doi-asserted-by":"publisher","first-page":"212570","DOI":"10.7573\/dic.212570","volume":"8","author":"AC Foulkes","year":"2019","unstructured":"Foulkes AC, Warren RB. Brodalumab in psoriasis: evidence to date and clinical potential. Drugs Context. 2019;8:212570.","journal-title":"Drugs Context"},{"issue":"5","key":"860_CR75","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1136\/annrheumdis-2020-218808","volume":"80","author":"X Baraliakos","year":"2021","unstructured":"Baraliakos X, Gossec L, Pournara E, et al. Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase\u00a03 MAXIMISE trial. Ann Rheum Dis. 2021;80(5):582\u201390.","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"860_CR76","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1093\/rheumatology\/kead705","volume":"63","author":"PJ Mease","year":"2024","unstructured":"Mease PJ, Gladman DD, Merola JF, et al. Comparative efficacy and safety of bimekizumab in psoriatic arthritis: a systematic literature review and network meta-analysis. Rheumatology (Oxford). 2024;63(7):1779\u201389.","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"860_CR77","doi-asserted-by":"publisher","first-page":"e005026","DOI":"10.1136\/rmdopen-2024-005026","volume":"11","author":"PJ Mease","year":"2025","unstructured":"Mease PJ, Gensler LS, Orbai AM, et al. Long-term safety of bimekizumab in adult patients with axial spondyloarthritis or psoriatic arthritis: pooled results from integrated phase\u00a0IIb\/III clinical studies. RMD Open. 2025;11(2):e005026.","journal-title":"RMD Open"},{"issue":"9","key":"860_CR78","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1136\/annrheumdis-2020-217927","volume":"79","author":"M Fauny","year":"2020","unstructured":"Fauny M, Moulin D, D'Amico F, et al. Paradoxical gastrointestinal effects of interleukin-17 blockers. Ann Rheum Dis. 2020;79(9):1132\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"860_CR79","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.jaad.2016.10.027","volume":"76","author":"K Reich","year":"2017","unstructured":"Reich K, Leonardi C, Langley RG, et al. Inflammatory bowel disease among patients with psoriasis treated with ixekizumab: a presentation of adjudicated data from an integrated database of 7 randomized controlled and uncontrolled trials. J Am Acad Dermatol. 2017;76(3):441-448.e2.","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"860_CR80","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2025.103818","volume":"24","author":"N Heidari","year":"2025","unstructured":"Heidari N, Heidari A, Eghbali S, et al. The role of interleukin inhibitors in the treatment of hidradenitis suppurativa; a systematic review of clinical trials. Autoimmun Rev. 2025;24(7):103818.","journal-title":"Autoimmun Rev"},{"issue":"10","key":"860_CR81","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2021.102902","volume":"20","author":"F Campanaro","year":"2021","unstructured":"Campanaro F, Batticciotto A, Zaffaroni A, Cappelli A, Donadini MP, Squizzato A. JAK inhibitors and psoriatic arthritis: a systematic review and meta-analysis. Autoimmun Rev. 2021;20(10):102902.","journal-title":"Autoimmun Rev"},{"issue":"3","key":"860_CR82","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1007\/s13555-023-00892-5","volume":"13","author":"C Samuel","year":"2023","unstructured":"Samuel C, Cornman H, Kambala A, Kwatra SG. A review on the safety of using JAK inhibitors in dermatology: clinical and laboratory monitoring. Dermatol Ther. 2023;13(3):729\u201349.","journal-title":"Dermatol Ther"},{"issue":"5","key":"860_CR83","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.1093\/rheumatology\/keae580","volume":"64","author":"A Kavanaugh","year":"2025","unstructured":"Kavanaugh A, Coates LC, Mease PJ, et al. Deucravacitinib, a selective, TYK2 inhibitor, in psoriatic arthritis: achievement of minimal disease activity components in a phase\u00a02 trial. Rheumatology (Oxford). 2025;64(5):2557\u201364.","journal-title":"Rheumatology (Oxford)"},{"key":"860_CR84","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20133318","volume":"20","author":"S Madonna","year":"2019","unstructured":"Madonna S, Girolomoni G, Dinarello CA, Albanesi C. The significance of IL-36\u00a0hyperactivation and IL-36R targeting in psoriasis. Int J Mol Sci. 2019;20:3318 (s.l.\u202f:).","journal-title":"Int J Mol Sci"},{"issue":"4","key":"860_CR85","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1016\/j.jaci.2014.09.043","volume":"135","author":"S Hussain","year":"2015","unstructured":"Hussain S, Berki DM, Choon SE, et al. IL36RN mutations define a severe autoinflammatory phenotype of generalized pustular psoriasis. J Allergy Clin Immunol. 2015;135(4):1067-1070.e9.","journal-title":"J Allergy Clin Immunol"},{"key":"860_CR86","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1093\/bjd\/ljac049","volume":"188","author":"F Ali","year":"2023","unstructured":"Ali F, Smith CH, Mahil SK. Spesolimab in the treatment of generalized pustular psoriasis: a critically appraised research paper. Br J Dermatol. 2023;188:328\u20139.","journal-title":"Br J Dermatol"},{"key":"860_CR87","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01210","volume":"9","author":"L Tang","year":"2018","unstructured":"Tang L, Yang X, Liang Y, Xie H, Dai Z, Zheng G. Transcription factor retinoid-related orphan receptor \u03b3t: a promising target for the treatment of psoriasis. Front Immunol. 2018;9:1210.","journal-title":"Front Immunol"},{"issue":"10","key":"860_CR88","doi-asserted-by":"publisher","first-page":"3809","DOI":"10.4049\/jimmunol.1602142","volume":"198","author":"A Zanin-Zhorov","year":"2017","unstructured":"Zanin-Zhorov A, Weiss JM, Trzeciak A, et al. Cutting edge: selective oral ROCK2 inhibitor reduces clinical scores in patients with psoriasis vulgaris and normalizes skin pathology via concurrent regulation of IL-17 and IL-10. J Immunol. 2017;198(10):3809\u201314.","journal-title":"J Immunol"},{"issue":"12","key":"860_CR89","doi-asserted-by":"publisher","first-page":"4160","DOI":"10.1038\/s41591-025-03971-6","volume":"31","author":"IB McInnes","year":"2025","unstructured":"McInnes IB, Coates LC, Mease PJ, et al. Sonelokimab, an IL-17A\/IL-17F-inhibiting nanobody for active psoriatic arthritis: a randomized, placebo-controlled phase\u00a02 trial. Nat Med. 2025;31(12):4160\u201371.","journal-title":"Nat Med"},{"issue":"6","key":"860_CR90","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1016\/j.ard.2025.02.019","volume":"84","author":"PC Taylor","year":"2025","unstructured":"Taylor PC, Mease PJ, de Vlam K, et al. Efficacy and safety of izokibep in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study. Ann Rheum Dis. 2025;84(6):979\u201391.","journal-title":"Ann Rheum Dis."},{"issue":"10","key":"860_CR91","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2025.103865","volume":"24","author":"AZ Lignou","year":"2025","unstructured":"Lignou AZ, Vassilakis KD, Baraliakos X, Sfikakis PP, Gottenberg JE, Fragoulis GE. Combination targeted therapy with two biologic\/targeted synthetic DMARDs in 1200 patients with immune mediated inflammatory diseases. A systematic literature review for current landscape in safety and efficacy. Autoimmun Rev. 2025;24(10):103865. https:\/\/doi.org\/10.1016\/j.autrev.2025.103865.","journal-title":"Autoimmun Rev"},{"issue":"1","key":"860_CR92","doi-asserted-by":"publisher","DOI":"10.1186\/s12955-020-01422-z","volume":"18","author":"LC Coates","year":"2020","unstructured":"Coates LC, Orbai AM, Azevedo VF, et al. Results of a global, patient-based survey assessing the impact of psoriatic arthritis discussed in the context of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire. Health Qual Life Outcomes. 2020;18(1):173.","journal-title":"Health Qual Life Outcomes"},{"issue":"2","key":"860_CR93","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-018-0120-8","volume":"5","author":"K de Vlam","year":"2018","unstructured":"de Vlam K, Merola JF, Birt JA, et al. Skin involvement in psoriatic arthritis worsens overall disease activity, patient-reported outcomes, and increases healthcare resource utilization: an observational, cross-sectional study. Rheumatol Ther. 2018;5(2):42.","journal-title":"Rheumatol Ther"},{"issue":"9","key":"860_CR94","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1136\/annrheumdis-2018-215003","volume":"78","author":"A Kavanaugh","year":"2019","unstructured":"Kavanaugh A, Gottlieb A, Morita A, et al. The contribution of joint and skin improvements to the health-related quality of life of patients with psoriatic arthritis: a post hoc analysis of two randomised controlled studies. Ann Rheum Dis. 2019;78(9):1215\u20139.","journal-title":"Ann Rheum Dis"},{"key":"860_CR95","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-025-01329-3","author":"F Proft","year":"2025","unstructured":"Proft F, Ribeiro AL, Singla S, et al. Consensus definitions of complex-to-manage and treatment-refractory psoriatic arthritis: a GRAPPA initiative. Nat Rev Rheumatol. 2025. https:\/\/doi.org\/10.1038\/s41584-025-01329-3.","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"860_CR96","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.ard.2025.10.002","volume":"85","author":"H Marzo-Ortega","year":"2026","unstructured":"Marzo-Ortega H, Harrison SR, Fragoulis GE, et al. EULAR points to consider and consensus definitions for difficult-to-manage and treatment-refractory psoriatic arthritis. Ann Rheum Dis. 2026;85(1):61\u201374.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"860_CR97","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1093\/rheumatology\/keae263","volume":"63","author":"KD Vassilakis","year":"2024","unstructured":"Vassilakis KD, Papagoras C, Fytanidis N, et al. Identification and characteristics of patients with potential difficult-to-treat psoriatic arthritis: exploratory analyses of the Greek PsA registry. Rheumatology (Oxford). 2024;63(9):2427\u201332.","journal-title":"Rheumatology (Oxford)."},{"issue":"4","key":"860_CR98","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1007\/s40744-022-00461-w","volume":"9","author":"FM Perrotta","year":"2022","unstructured":"Perrotta FM, Scriffignano S, Ciccia F, Lubrano E. Clinical characteristics of potential \u201cdifficult-to-treat\u201d patients with psoriatic arthritis: a retrospective analysis of a longitudinal cohort. Rheumatol Ther. 2022;9(4):1193\u2013201.","journal-title":"Rheumatol Ther"},{"key":"860_CR99","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2023.152275","volume":"63","author":"C Philippoteaux","year":"2023","unstructured":"Philippoteaux C, Marty-Ane A, Cailliau E, et al. Characteristics of difficult-to-treat psoriatic arthritis: a comparative analysis. Semin Arthritis Rheum. 2023;63:152275.","journal-title":"Semin Arthritis Rheum"}],"container-title":["Rheumatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-026-00860-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40744-026-00860-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-026-00860-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T17:08:00Z","timestamp":1785517680000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40744-026-00860-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,18]]},"references-count":99,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["860"],"URL":"https:\/\/doi.org\/10.1007\/s40744-026-00860-3","relation":{},"ISSN":["2198-6576","2198-6584"],"issn-type":[{"value":"2198-6576","type":"print"},{"value":"2198-6584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,18]]},"assertion":[{"value":"21 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Konstantinos Tsafis, Vasileios Skepastianos, Elpida Skouvaklidou, Dimitrios Deligeorgakis, Maria Boutel, Aikaterini Kontonikola, Nikolaos Papazoglou, George E. Fragoulis, and Nikolaos Kougkas declare that they have no conflicts of interest relevant to this work.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}